References
1. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K.
Survival in Duchenne muscular dystrophy: improvements in life expectancy
since 1967 and the impact of home nocturnal ventilation.Neuromuscul Disord. 2002;12(10):926-929.
2. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular
dystrophy–the additive effect of spinal surgery and home nocturnal
ventilation in improving survival. Neuromuscul Disord.2007;17(6):470-475.
3. Passamano L, Taglia A, Palladino A, et al. Improvement of survival in
Duchenne Muscular Dystrophy: retrospective analysis of 835 patients.Acta Myol. 2012;31(2):121-125.
4. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J,
Lochmuller H. Life expectancy at birth in Duchenne muscular dystrophy: a
systematic review and meta-analysis. Eur J Epidemiol. 2020.
5. Rall S, Grimm T. Survival in Duchenne muscular dystrophy. Acta
Myol. 2012;31(2):117-120.
6. Saito T, Kawai M, Kimura E, et al. Study of Duchenne muscular
dystrophy long-term survivors aged 40 years and older living in
specialized institutions in Japan. Neuromuscul Disord.2017;27(2):107-114.
7. Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of
ataluren: comparison of results from the STRIDE Registry and CINRG DMD
Natural History Study. J Comp Eff Res. 2020;9(5):341-360.
8. Khan N, Eliopoulos H, Han L, et al. Eteplirsen Treatment Attenuates
Respiratory Decline in Ambulatory and Non-Ambulatory Patients with
Duchenne Muscular Dystrophy. J Neuromuscul Dis.2019;6(2):213-225.
9. Salmaninejad A, Jafari Abarghan Y, Bozorg Qomi S, et al. Common
therapeutic advances for Duchenne muscular dystrophy (DMD). Int J
Neurosci. 2020:1-20.
10. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin
production with golodirsen in patients with Duchenne muscular dystrophy.Neurology. 2020;94(21):e2270-e2282.
11. Moretti A, Fonteyne L, Giesert F, et al. Somatic gene editing
ameliorates skeletal and cardiac muscle failure in pig and human models
of Duchenne muscular dystrophy. Nat Med. 2020;26(2):207-214.
12. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of Systemic
Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne
Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA
Neurol. 2020.
13. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the
muscular dystrophies. Muscle Nerve. 1981;4(2):155-164.
14. Humbertclaude V, Hamroun D, Bezzou K, et al. Motor and respiratory
heterogeneity in Duchenne patients: implication for clinical trials.Eur J Paediatr Neurol. 2012;16(2):149-160.
15. Wang M, Birnkrant DJ, Super DM, Jacobs IB, Bahler RC. Progressive
left ventricular dysfunction and long-term outcomes in patients with
Duchenne muscular dystrophy receiving cardiopulmonary therapies.Open Heart. 2018;5(1):e000783.
16. Birnkrant DJ, Ashwath ML, Noritz GH, et al. Cardiac and pulmonary
function variability in Duchenne/Becker muscular dystrophy: an initial
report. J Child Neurol. 2010;25(9):1110-1115.
17. Jin JB, Carter JC, Sheehan DW, Birnkrant DJ. Cardiopulmonary
phenotypic discordance is common in Duchenne muscular dystrophy.Pediatr Pulmonol. 2019;54(2):186-193.
18. Ashwath ML, Jacobs IB, Crowe CA, Ashwath RC, Super DM, Bahler RC.
Left ventricular dysfunction in duchenne muscular dystrophy and
genotype. Am J Cardiol. 2014;114(2):284-289.
19. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in
spirometry over time as a prognostic marker in patients with Duchenne
muscular dystrophy. Am J Respir Crit Care Med.2001;164(12):2191-2194.
20. Birnkrant DJ, Ararat E, Mhanna MJ. Cardiac phenotype determines
survival in Duchenne muscular dystrophy. Pediatr Pulmonol.2016;51(1):70-76.
21. McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients
with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a
multicentre, randomised, double-blind, placebo-controlled, phase 3
trial. Lancet. 2017;390(10101):1489-1498.
22. Shimizu-Motohashi Y, Murakami T, Kimura E, Komaki H, Watanabe N.
Exon skipping for Duchenne muscular dystrophy: a systematic review and
meta-analysis. Orphanet J Rare Dis. 2018;13(1):93.
23. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the
treatment of Duchenne muscular dystrophy. Ann Neurol.2013;74(5):637-647.
24. Buyse GM, Goemans N, van den Hauwe M, et al. Idebenone as a novel,
therapeutic approach for Duchenne muscular dystrophy: results from a 12
month, double-blind, randomized placebo-controlled trial.Neuromuscul Disord. 2011;21(6):396-405.
25. Servais L, Straathof CSM, Schara U, et al. Long-term data with
idebenone on respiratory function outcomes in patients with Duchenne
muscular dystrophy. Neuromuscul Disord. 2020;30(1):5-16.
26. Bello L, Pegoraro E. The ”Usual Suspects”: Genes for Inflammation,
Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular
Dystrophy. J Clin Med. 2019;8(5).
27. Spitali P, Zaharieva I, Bohringer S, et al. TCTEX1D1 is a genetic
modifier of disease progression in Duchenne muscular dystrophy.Eur J Hum Genet. 2020;28(6):815-825.
28. Yamamoto T, Awano H, Zhang Z, et al. Cardiac Dysfunction in Duchenne
Muscular Dystrophy Is Less Frequent in Patients With Mutations in the
Dystrophin Dp116 Coding Region Than in Other Regions. Circ Genom
Precis Med. 2018;11(1):e001782.
29. Vo AH, McNally EM. Modifier genes and their effect on Duchenne
muscular dystrophy. Curr Opin Neurol. 2015;28(5):528-534.
30. Van Dorn CS, Puchalski MD, Weng HY, Bleyl SB, Butterfield RJ,
Williams RV. DMD mutation and LTBP4 haplotype do not predict onset of
left ventricular dysfunction in Duchenne muscular dystrophy.Cardiol Young. 2018;28(7):910-915.
31. Bello L, D’Angelo G, Villa M, et al. Genetic modifiers of
respiratory function in Duchenne muscular dystrophy. Ann Clin
Transl Neurol. 2020;7(5):786-798.
32. Vianello S, Pantic B, Fusto A, et al. SPP1 genotype and
glucocorticoid treatment modify osteopontin expression in Duchenne
muscular dystrophy cells. Hum Mol Genet. 2017;26(17):3342-3351.